{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "In the Parkinson disease (PD) brain, neuropathological evaluation reveals substantial loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of insoluble cytoplasmic inclusions (Lewy bodies) containing aggregated proteins... Strong genetic and experimental data have linked several autosomal dominant parkinsonian syndromes to three human mutations in the gene encoding for a-synuclein... Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of Parkinson disease as involving a-synuclein aggregation leading to Lewy body formation and dopaminergic neuron loss, directly relevant to the functional assays described."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In this study, we have examined the effect of over-expression of HO-1 on the stability of a-synuclein in M17 neuroblastoma cells... we report that over-expression of HO-1 triggers intracellular proteosomal degradation of a-synuclein. Interestingly, a-synuclein carrying A30P mutation associated with familial form of PD, displayed remarkable resistance to proteosomal degradation triggered by HO-1.",
          "judgment": "Yes",
          "reasoning": "The assay used (proteosomal degradation assay in neuroblastoma cells with HO-1 over-expression) models a critical aspect of PD pathogenesis, i.e., the failure of protein degradation leading to aggregation, which is directly tied to the disease mechanism of a-synuclein accumulation and Lewy body formation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Human neuroblastoma M17 cells were transfected with various doses of HO-1 cDNA... native a-synuclein protein concentration progressively decreased with increasing levels of HO-1 expression... Myc-a-synuclein (WT) and Myc-a-synuclein (A30P) were co-transfected with HO-1... Relative amounts of proteins were determined by western blot... Statistical analyses were performed by one-way ANOVA followed by Newman-Keuls post hoc comparisons... experiments involved multiple conditions and doses.",
          "judgment": "Yes",
          "reasoning": "The paper includes wild-type a-synuclein as a negative/normal control and compares it against the A30P mutant. While explicit mention of 'null' controls is not detailed for every experiment, the use of mock-transfected cells and dose-dependent HO-1 transfection serves as a control framework. Replicates are implied through statistical analysis (ANOVA) and multiple experimental conditions, though not explicitly stated as 'n=3 independent experiments'. Both conditions are sufficiently met.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "To evaluate the effect of the A30P mutation, we co-transfected Myc-a-synuclein (WT) or Myc-a-synuclein (A30P) with different amounts of HO-1 cDNA... Myc-a-synuclein (A30P) displayed remarkable resistance to HO-1-induced proteosomal degradation... A53T mutation did not affect a-synuclein degradation significantly in HO-1 over-expressing cells.",
          "judgment": "Yes",
          "reasoning": "The study uses wild-type a-synuclein as a benign control and compares it with the A30P mutant, which is a known pathogenic variant associated with familial PD. Additionally, the A53T mutation (another known pathogenic variant) is tested, providing further variant control context. This meets the criteria for using known benign and pathogenic controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analyses were performed by one-way ANOVA followed by Newman-Keuls post hoc comparisons to assess significant main effects within groups. Statistical significance was set at p < 0.05... Blot band quantification determined that in cells transfected with 4, 8 and 12 lg HO-1, the amounts of a-synuclein protein were, respectively, 16.1%, 39.5% and 47.3% lower relative to sham-transfected cells... In cells transfected with 4, 8 and 12 lg of HO-1, Myc-a-synuclein (A30P) levels were 95%, 105%, and 110% of basal level.",
          "judgment": "No",
          "reasoning": "While statistical analyses (ANOVA) are performed and significance levels are reported, there is no direct calculation or estimation of OddsPath (a quantitative measure of pathogenicity likelihood) for the A30P variant's functional impact. The data provided are relative protein levels and statistical significance, but not a direct likelihood ratio or equivalent metric for pathogenicity.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "To evaluate the effect of the A30P mutation, we co-transfected Myc-a-synuclein (WT) or Myc-a-synuclein (A30P) with different amounts of HO-1 cDNA... To examine the effect of A53T mutation, we co-transfected HO-1 with a-synuclein (WT) or A53T... Myc-a-synuclein (WT) and A53T levels decreased significantly with HO-1 over-expression, while A30P did not.",
          "judgment": "10 or less",
          "reasoning": "The study explicitly tests two variant controls: wild-type (benign) and A53T (pathogenic), alongside A30P. The total number of benign/pathogenic variant controls used is less than 11 (specifically, 2 variants: WT and A53T), which limits the strength of evidence to supporting level as per ACMG guidelines.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA A30P is rated as PS3_supporting due to the clear demonstration of resistance to HO-1-induced proteosomal degradation compared to wild-type, aligning with its pathogenic role in promoting a-synuclein aggregation in PD. However, the lack of OddsPath calculation and limited number of variant controls (less than 11) restricts the strength to supporting level."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "In the Parkinson disease (PD) brain, neuropathological evaluation reveals substantial loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of insoluble cytoplasmic inclusions (Lewy bodies) containing aggregated proteins... Strong genetic and experimental data have linked several autosomal dominant parkinsonian syndromes to three human mutations in the gene encoding for a-synuclein... Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of Parkinson disease as involving a-synuclein aggregation leading to Lewy body formation and dopaminergic neuron loss, directly relevant to the functional assays described."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In this study, we have examined the effect of over-expression of HO-1 on the stability of a-synuclein in M17 neuroblastoma cells... we report that over-expression of HO-1 triggers intracellular proteosomal degradation of a-synuclein... A53T mutation did not affect a-synuclein degradation significantly in HO-1 over-expressing cells.",
          "judgment": "Yes",
          "reasoning": "The assay used (proteosomal degradation assay in neuroblastoma cells with HO-1 over-expression) models a critical aspect of PD pathogenesis, i.e., the failure of protein degradation leading to aggregation, which is directly tied to the disease mechanism of a-synuclein accumulation and Lewy body formation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Human neuroblastoma M17 cells were transfected with various doses of HO-1 cDNA... native a-synuclein protein concentration progressively decreased with increasing levels of HO-1 expression... Myc-a-synuclein (WT) and Myc-a-synuclein (A53T) were co-transfected with HO-1... Relative amounts of proteins were determined by western blot... Statistical analyses were performed by one-way ANOVA... experiments involved multiple conditions and doses.",
          "judgment": "Yes",
          "reasoning": "The paper includes wild-type a-synuclein as a negative/normal control and compares it against the A53T mutant. While explicit mention of 'null' controls is not detailed for every experiment, the use of mock-transfected cells and dose-dependent HO-1 transfection serves as a control framework. Replicates are implied through statistical analysis (ANOVA) and multiple experimental conditions, though not explicitly stated as 'n=3 independent experiments'. Both conditions are sufficiently met.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "To examine the effect of A53T mutation, we co-transfected HO-1 with a-synuclein (WT) or A53T... A53T mutation did not affect a-synuclein degradation significantly in HO-1 over-expressing cells... Myc-a-synuclein (WT) levels decreased with HO-1 over-expression.",
          "judgment": "Yes",
          "reasoning": "The study uses wild-type a-synuclein as a benign control and compares it with the A53T mutant, which is a known pathogenic variant associated with familial PD. Additionally, the A30P mutation (another known pathogenic variant) is tested in parallel experiments, providing further variant control context. This meets the criteria for using known benign and pathogenic controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analyses were performed by one-way ANOVA followed by Newman-Keuls post hoc comparisons to assess significant main effects within groups. Statistical significance was set at p < 0.05... The amount of A53T in HO-1 expressing cells was 10.8% of those expressing mock construct.",
          "judgment": "No",
          "reasoning": "While statistical analyses (ANOVA) are performed and significance levels are reported, there is no direct calculation or estimation of OddsPath for the A53T variant's functional impact. The data provided are relative protein levels and statistical significance, but not a direct likelihood ratio or equivalent metric for pathogenicity.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "To evaluate the effect of the A30P mutation, we co-transfected Myc-a-synuclein (WT) or Myc-a-synuclein (A30P) with different amounts of HO-1 cDNA... To examine the effect of A53T mutation, we co-transfected HO-1 with a-synuclein (WT) or A53T... Myc-a-synuclein (WT) and A53T levels decreased significantly with HO-1 over-expression.",
          "judgment": "10 or less",
          "reasoning": "The study explicitly tests two variant controls: wild-type (benign) and A30P (pathogenic), alongside A53T. The total number of benign/pathogenic variant controls used is less than 11 (specifically, 2 variants: WT and A30P), which limits the strength of evidence to supporting level as per ACMG guidelines.",
          "next_step_or_outcome": "Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA A53T is rated as BS3_supporting because the variant does not show resistance to HO-1-induced proteosomal degradation, behaving similarly to wild-type a-synuclein, which suggests a benign functional impact in this specific assay context. However, the lack of OddsPath calculation and limited number of variant controls (less than 11) restricts the strength to supporting level."
    }
  ]
}